Citi analyst Joanne Wuensch raised the firm’s price target on Insulet (PODD) to $380 from $320 and keeps a Buy rating on the shares following the Q1 report. The firm also removed Insulet as a Top Pick in place of Edwards Lifesciences (EW). The analyst cites the stock’s 25% year-to-date move and almost 72% over the last year for removing it as a top pick.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Citi ups Edwards Lifesciences target, names Top Pick
- Insulet price target raised to $375 from $355 at Bernstein
- Coinbase, Caterpillar upgraded: Wall Street’s top analyst calls
- Insulet upgraded to Outperform from Peer Perform at Wolfe Research
- Insulet’s Strong Performance and Growth Potential Justifies Buy Rating